bioRxivCancer BiologyPreprint
Loss of ESE3/EHF is sufficient to promote cell plasticity, transformation and androgen-independent status in the early stage of prostate carcinogenesis.
Domenico AlbinoiD, Giada SandriniiD, Carola MusumeciiD, Elisa StorelliiD, Giovanni Papa, Daniela ImpellizzieriiD, Alessia CacciatoreiD, Giada Andrea CassanmagnagoiD, Atik Balla, Simone MosoleiD, Gianluca CivenniiD, Andrea RinaldiiD, Cármen JerónimoiD, Rui HenriqueiD, Marco BolisiD, Carlo Vittorio CatapanoiD, Giuseppina Maria CarboneiD
Abstract
Phenotypic plasticity enables tumor progression and treatment resistance. However, its timing and underlying mechanisms are poorly understood. Here, we demonstrate that cell plasticity can emerge early during prostate cancer development, resulting from the knockout of the epithelial-specific ETS transcription factor EHF in prostate epithelial cells. Inspecting the transcriptome of human prostate cancers, we identified a correlation between low EHF expression, loss of luminal epithelial identity, and attenuated androgen signaling in both primary tumors and castration-resistant prostate cancers (CRPC). In EHF knockout mouse models and human epithelial cells, EHF ablation was sufficient to disrupt epithelial cell lineage integrity and promote a progenitor/stem cell-like state with both basal and luminal features, enabling high plasticity and multi-lineage phenotypic transitions. Mechanistically, EHF acted as a central node controlling a hierarchy of transcriptional regulatory factors and downstream signaling pathways (e.g., COL1A1/DDR1, JAK/STAT3), thereby regulating epithelial lineage integrity and restricting stemness and phenotypic transitions. Activation of these downstream pathways, consequent to EHF loss, promoted non-luminal cell features, attenuated androgenic response, and resistance to AR antagonists. Collectively, these data provide novel insights into the causes of phenotypic plasticity and androgen indifference already at the early stages of prostate tumorigenesis and a new perspective on the paths to cancer progression directly relevant to the development of more efficient treatment strategies.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling
S. Zaidi, J. L. Zhao, … C. L. Sawyers·bioRxiv·Nov 1, 2021
- EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer
Beatriz German, Katherine L. Morel, … Leigh Ellis·bioRxiv·Aug 7, 2025
- Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer
R. Jindal, A. Nanda, … M. K. Jolly·Computational and Structural Biotechnology JournalPeer-reviewed·Jan 1, 2023
- EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer
Justine J. Jacobi, Kristine M. Wadosky, … David W. Goodrich·bioRxiv·May 13, 2025
- Engulfing to Adapt: Efferocytosis by Epithelial Cells Triggers Cell State Transitions During Tissue Remodeling
Adda-Lee Graham-Paquin, Deepak Saini, … Luke Martin McCaffrey·bioRxiv·Jul 31, 2025
- p21(CIP1/WAF1)-mediated partial senescence supports steroidogenesis and therapy resistance in primary prostate cancer cultures
Emily Toscano, Valentina Maggio, … Rosanna Paciucci·bioRxiv·Jan 16, 2026